NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
TRACRIUM (atracurium besylate) by Pfizer is clinical pharmacology atracurium besylate is a nondepolarizing skeletal muscle relaxant. First approved in 1983.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRACRIUM (atracurium besylate) is a nondepolarizing neuromuscular blocking agent used during anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery. It works by competitively antagonizing acetylcholine at the motor end-plate, with a duration of action approximately one-third to one-half that of older agents like pancuronium. The drug's effects are rapidly reversible with acetylcholinesterase inhibitors.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on defending market position rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Atracurium besylate is a nondepolarizing skeletal muscle relaxant. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular…
Worked on TRACRIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.